Version: 12th June 2020

Author Disclosure Form

Manuscript title __________________________________________________Corresponding author __________________________________________________Affiliation __________________________________________________Tel. __________________________________________________E-mail __________________________________________________Co-authors __________________________________________________

__________________________________________________Corresponding author signature __________________________________________________

To reduce errors in the way that names appear when they are abbreviated, please fill in the following table for all authors:

First name(s) Surname/Family name Name as it should appear in abbreviated form

E.g., Jane Louise Doe Doe JL

Please add extra rows as needed.

Future Science Group would like to keep you updated with relevant journal and company news. Please click here to select your email preferences.

Please note, you will also be able to update your email preferences via the link within the footer of any email communication you receive, or by contacting the Editorial office directly at info@future-science-group.com.

Social mediaFuture Science Group journals will share published articles via our social media channels (see here for Future Medicine journals, and here for Newlands Press/Future Science journals, for links to follow our journals’ social sites).

If you have any queries or concerns about sharing your article via social media, please contact the Editor at any point.

Using appropriate hashtags or @mentioning you/your co-authors, institution, funders, etc. is a great way to increase to discoverability of a tweet mentioning your article. If you have any suggestions of hashtags or accounts you’d suggest we mention when sharing your work, please include them here:

E.g., @futuresciencegp; #science

1

Version: 12th June 2020

Please check the boxes below as appropriate

1.Author responsibility(Sections a AND b should be completed)

a) I certify that the manuscript represents valid work and that neither this manuscript nor one with substantially similar content under my authorship has been published or is being considered for publication elsewhere.

ANDb) I certify that I am the corresponding author for this manuscript. The manuscript is

submitted with the knowledge and on behalf of the listed co-authors.

2.Authorship I certify that each co-author listed on page 1 participated sufficiently in the work to take

responsibility for the content, and that all those who qualify are listed. Authorship credit should be based on (a) substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (b) drafting the work or revising it critically for important intellectual content; AND (c) final approval of the version to be published; AND (d) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Conditions (a), (b), (c) and (d) must all be met.

3.Contributors (who do not qualify for full authorship)

I certify that individuals in addition to the listed co-authors contributed to this publication, but do not fulfil all four authorship conditions (a–d) listed above. These individuals are listed below and acknowledged in the manuscript. Types of contributors include, but are not limited to: statisticians, medical writers and research personnel.

Name Affiliation Email Contribution

Please add extra rows as needed.OR

I certify that no individuals other than the listed co-authors contributed to this publication.

2

Version: 12th June 2020

4.Financial and conflict of interest disclosures(Sections a, b AND c should be completed)

a) Disclosure of financial support for the current work I certify that financial and/or material support was received for this research and/or the

creation of this work, the sources and extent of involvement of which are clearly identified in the manuscript.

OR I certify that no financial and/or material support was received for this research or the

creation of this work.

b) Author conflict of interest disclosures I certify that one or more of the authors have financial and/or nonfinancial relationships

with an organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, which have been disclosed in the manuscript.

Authors should disclose relationships in which they (or a close family member): are employed, are a contractor, provide services, or have otherwise collaborated in commercial or scientific pursuits – even in the absence of direct monetary remuneration. Stock holdings and issued or pending patents of an author or family member should also be disclosed. A 36-month disclosure window should be used.

OR I certify that none of the authors have any relevant financial and/or nonfinancial

relationships to disclose as defined in the point above.

c) Writing assistance disclosure I certify that funded writing assistance was utilised in the production of this manuscript, and

that this is disclosed, along with any sources of funding for such assistance, in the manuscript.OR

I certify that no funded writing assistance was utilised in the production of this manuscript.

Details of all relevant financial/material support, and financial and/or nonfinancial relationships (or the lack of) must be declared in the ‘Disclosure’ section of the manuscript for all authors.

3

Version: 12th June 2020

5.Ethical conduct of research disclosure (for papers including original data involving humans or animals only)

(Please check either or both boxes below as appropriate)

For studies involving data relating to human or animal experimental investigations, appropriate institutional review board approval has been obtained and is described within the article (for those investigators who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki have been followed).

For investigations involving human subjects, informed consent has been obtained from the participants involved and an explanation of how this was obtained is included in the manuscript.

Details of all ethical approval information and/or informed consent (or the lack of) must be declared in the ‘Disclosure’ section of the manuscript.

4

Version: 12th June 2020

6.Reporting the results of Clinical TrialsDoes your manuscript report the original results of a clinical trial?

Yes No

If Yes:(Sections a AND b should be completed)

a) Please state the clinical trial registration number here: _______________________________

b) Please complete the table below, which will form the basis of a data sharing statement* within the article should it be accepted for publication (compulsory for all papers reporting clinical trial data):

Will individual, de-identified participant data be available (including data dictionaries)?What data in particular will be shared?What other documents will be available, if any (e.g., study protocol, statistical analysis plan, etc.)?When will data be available (start and end dates)?By what access criteria will data be shared? To include:

- With whom?- For what types of analyses?- By what mechanism?

*From 1st July 2018, the International Committee of Medical Journal Editors (ICMJE) requires that all manuscripts that report the results of clinical trials must contain a data sharing statement, as described on their website here: http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. Illustrative examples of acceptable data sharing statements to complete the table above are included on the same webpage.

7.Secondary analysesDoes your manuscript report the secondary analysis of clinical trial data that have been shared with you?

Yes No

If Yes:(Sections a AND b should be completed)

a) I certify that the use of shared data was in accordance with the terms (if any) agreed to upon their receipt

b) Please state the source of the data using its unique, persistent identifier (this should also be referenced in the manuscript): __________________________________________________

5

Version: 12th June 2020

8.Copyright status of figures and tablesPlease complete the following table to indicate the copyright status of the figures and tables included in your manuscript. Each figure and table should be listed, and the appropriate column completed. Where permission is required and has been obtained, please attach the relevant licence agreement.

Figure/table number Is the figure/table original (prepared for current manuscript and not previously published)? (Y/N)

If no, please provide a link to the original source below

If no, please confirm the permission status of the figure/tablePermission obtained and copy provided to the Editor

OR:

Permission not required – REASON*

Please add extra rows as needed.

*If permission is not required to re-use a figure/table, authors should state the reason for this. Examples of reasons permission may not be required for a previously published figure/table include:

The figure/table was previously published in a journal published by an STM signatory publisher. Further information on this is available in our Author Guidelines (see here for Future Medicine journals, and here for Newlands Press/Future Science journals), and a list of STM signatory publishers is available at: https://www.stm-assoc.org/intellectual-property/permissions/permissions-guidelines/

The figure/table was previously published Open Access (if so, please ensure a link to the original article is provided in the table above) You were the author of the previously published figure/table, in a journal that permits the author to re-use content in subsequent publications (this

information is usually available on the journal website, or in any publishing agreement form you may have completed)

If you believe permission for re-use is not required for a reason other than the above, please discuss with the journal Editor on submission.If you have any queries, please contact the Editorial Office by e-mail or telephone (+44 [0]20 8371 6090).

6

Version: 12th June 2020

9.FSG Digital Hubs

You may be aware that Future Science Group publishes a number of digital hubs; free-of-charge websites open to all healthcare professionals. Sites include:

3DMedNet (www.3dmednet.com) BioanalysisZone (www.bioanalysis-zone.com) BioTechniques (www.biotechniques.com) Infectious Diseases Hub (www.id-hub.com) Neuro Central (www.neuro-central.com) Oncology Central (www.oncology-central.com) RegMedNet (www.regmednet.com) The Evidence Base (www.evidencebaseonline.com) The Nanomed Zone (www.nanomedzone.com)

Benefits include: Easy access to free peer-reviewed articles, from impact factored, Medline journals Fast access to the latest news and features Information you can trust, selected by experts Exciting multimedia content, including webinars and video interviews

If you would like access to any of these, please visit the site above and complete the simple sign-up process.

10. Video Journal of Biomedicine

The Video Journal of Biomedicine is a new platform from the Future Science Group that complements our peer-reviewed journals. VJBM provides a platform for authors to present their latest research or discuss their recently published, peer-reviewed paper in a short, high-quality, open access, interview-style video. Each video, published alongside your article as well as on the VJBM platform, provides you with the opportunity to personally discuss your latest work in more detail; highlighting its importance to the field, placing it in context, and discussing future implications. By watching the video, readers will gain a comprehensive understanding of the subject.

For an example please visit here.

Please email Joanne Walker, Publisher, Video Journal of Biomedicine for more information.

7